Genentech

August 27, 2020August 27, 2020

Venclexta Plus Vidaza Increases AML Survival, Study Shows

News

Adding Venclexta (venetoclax) to treatment with Vidaza (azacitidine) significantly prolongs survival in people with acute myeloid leukemia (AML) who have not been treated before, a new study demonstrates. The study, ... Read more

July 6, 2020July 6, 2020

Venclexta Combo Continues to Help Untreated AML Patients in Phase 3 Trial

News

When given alongside Vidaza (azacitidine), Venclexta (venetoclax) elicits clinically meaningful responses and prolongs survival in untreated acute myeloid leukemia (AML) patients who are not eligible for intense chemotherapy, a Phase 3 ... Read more

May 28, 2020May 28, 2020

Venclexta Plus Vidaza Improves Survival for AML Patients, AbbVie Reports

News

First-line treatment with a combination of Venclexta (venetoclax) and Vidaza (azacitidine) significantly extended survival in people with acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy, as compared with Vidaza alone, AbbVie ... Read more

April 24, 2020April 24, 2020

NORD Opens COVID-19 Financial Aid Program for Rare Disease Community

News, syndicated

The National Organization for Rare Disorders (NORD) has opened a financial assistance program for people in rare disease community who are affected by the COVID-19 pandemic in the U.S. Called ... Read more

March 13, 2020March 23, 2020

Venclexta-Cytarabine Fails to Significantly Prolong Life in Untreated AML Patients, Trial Shows

News

First-line treatment with a combination of Venclexta (venetoclax) and a low dose of cytarabine failed to significantly extend the survival of people with acute myeloid leukemia (AML) who were ineligible ... Read more